| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 25 | 2024 | 69 | 11.090 |
Why?
|
| Pancreatitis | 38 | 2024 | 50 | 10.880 |
Why?
|
| Carcinoma, Pancreatic Ductal | 11 | 2023 | 22 | 6.020 |
Why?
|
| Pancreatitis, Chronic | 13 | 2024 | 19 | 3.930 |
Why?
|
| Stomach Neoplasms | 7 | 2024 | 42 | 3.480 |
Why?
|
| Pancreatitis, Acute Necrotizing | 12 | 2019 | 12 | 2.590 |
Why?
|
| Middle Aged | 63 | 2024 | 7885 | 2.550 |
Why?
|
| Humans | 98 | 2024 | 17376 | 2.540 |
Why?
|
| Male | 69 | 2024 | 9843 | 2.380 |
Why?
|
| Severity of Illness Index | 21 | 2024 | 439 | 2.240 |
Why?
|
| Retrospective Studies | 35 | 2024 | 2428 | 2.230 |
Why?
|
| Aged | 46 | 2024 | 6129 | 2.120 |
Why?
|
| Pancreatic Cyst | 5 | 2017 | 5 | 2.030 |
Why?
|
| Female | 65 | 2024 | 12444 | 2.000 |
Why?
|
| Acute Disease | 26 | 2024 | 144 | 1.860 |
Why?
|
| Hospitalization | 8 | 2019 | 805 | 1.830 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2023 | 203 | 1.800 |
Why?
|
| Pancreas | 9 | 2023 | 14 | 1.690 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 455 | 1.680 |
Why?
|
| Risk Assessment | 17 | 2024 | 1079 | 1.530 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 537 | 1.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 165 | 1.510 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 1942 | 1.480 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 102 | 1.470 |
Why?
|
| Simvastatin | 5 | 2022 | 11 | 1.410 |
Why?
|
| Risk Factors | 22 | 2024 | 3255 | 1.350 |
Why?
|
| Natural Language Processing | 2 | 2020 | 60 | 1.260 |
Why?
|
| Adult | 36 | 2024 | 7529 | 1.200 |
Why?
|
| Early Detection of Cancer | 6 | 2024 | 529 | 1.200 |
Why?
|
| Precancerous Conditions | 2 | 2022 | 48 | 1.190 |
Why?
|
| Incidence | 13 | 2024 | 1266 | 1.160 |
Why?
|
| Triglycerides | 3 | 2020 | 83 | 1.160 |
Why?
|
| Prognosis | 16 | 2024 | 604 | 1.110 |
Why?
|
| Multiple Organ Failure | 7 | 2023 | 10 | 1.080 |
Why?
|
| Predictive Value of Tests | 11 | 2024 | 342 | 1.030 |
Why?
|
| Ethnic Groups | 3 | 2016 | 456 | 1.020 |
Why?
|
| Cohort Studies | 19 | 2024 | 2526 | 1.010 |
Why?
|
| Blood Urea Nitrogen | 5 | 2021 | 8 | 0.930 |
Why?
|
| California | 10 | 2024 | 2317 | 0.910 |
Why?
|
| Health Status Disparities | 2 | 2018 | 148 | 0.900 |
Why?
|
| Colonoscopy | 3 | 2015 | 257 | 0.890 |
Why?
|
| Prospective Studies | 13 | 2022 | 1229 | 0.890 |
Why?
|
| Colorectal Neoplasms | 3 | 2015 | 627 | 0.890 |
Why?
|
| Disease Management | 3 | 2021 | 127 | 0.830 |
Why?
|
| Hematocrit | 4 | 2021 | 6 | 0.830 |
Why?
|
| Pancreatic Ducts | 4 | 2020 | 6 | 0.830 |
Why?
|
| Population Surveillance | 2 | 2015 | 254 | 0.820 |
Why?
|
| Length of Stay | 10 | 2024 | 171 | 0.820 |
Why?
|
| Fluid Therapy | 4 | 2019 | 10 | 0.800 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 7 | 0.790 |
Why?
|
| Eating | 2 | 2021 | 34 | 0.790 |
Why?
|
| Hypertriglyceridemia | 2 | 2020 | 12 | 0.760 |
Why?
|
| Stomach | 3 | 2021 | 4 | 0.740 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 246 | 0.740 |
Why?
|
| Endosonography | 4 | 2017 | 9 | 0.730 |
Why?
|
| Patient Readmission | 3 | 2019 | 165 | 0.720 |
Why?
|
| Social Justice | 1 | 2021 | 6 | 0.720 |
Why?
|
| Metformin | 1 | 2021 | 50 | 0.710 |
Why?
|
| United States | 16 | 2024 | 3891 | 0.710 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 702 | 0.710 |
Why?
|
| Pancreatic Function Tests | 8 | 2014 | 8 | 0.690 |
Why?
|
| Glycated Hemoglobin A | 2 | 2020 | 184 | 0.670 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 114 | 0.650 |
Why?
|
| Analgesics | 2 | 2019 | 27 | 0.650 |
Why?
|
| Systemic Inflammatory Response Syndrome | 5 | 2021 | 9 | 0.650 |
Why?
|
| Patient Transfer | 2 | 2010 | 25 | 0.650 |
Why?
|
| Time Factors | 9 | 2020 | 1044 | 0.630 |
Why?
|
| Biomarkers | 7 | 2024 | 306 | 0.620 |
Why?
|
| Early Ambulation | 1 | 2019 | 3 | 0.620 |
Why?
|
| Telemedicine | 1 | 2022 | 182 | 0.620 |
Why?
|
| Hemoglobins | 2 | 2009 | 37 | 0.620 |
Why?
|
| Lovastatin | 2 | 2016 | 7 | 0.620 |
Why?
|
| Endoscopy, Digestive System | 7 | 2014 | 10 | 0.620 |
Why?
|
| Pharmaceutical Preparations | 1 | 2018 | 11 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 666 | 0.560 |
Why?
|
| Panniculitis | 1 | 2017 | 1 | 0.560 |
Why?
|
| Patient Admission | 4 | 2015 | 69 | 0.560 |
Why?
|
| Arthritis | 1 | 2017 | 6 | 0.560 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 8 | 0.560 |
Why?
|
| ROC Curve | 8 | 2021 | 73 | 0.530 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 538 | 0.520 |
Why?
|
| Patient Preference | 1 | 2017 | 49 | 0.520 |
Why?
|
| Hospital Mortality | 4 | 2009 | 135 | 0.520 |
Why?
|
| Metaplasia | 3 | 2022 | 7 | 0.510 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 112 | 0.510 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 174 | 0.500 |
Why?
|
| European Continental Ancestry Group | 5 | 2020 | 480 | 0.460 |
Why?
|
| Endoscopy | 3 | 2020 | 10 | 0.460 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 395 | 0.450 |
Why?
|
| Survival Rate | 6 | 2016 | 253 | 0.440 |
Why?
|
| Gastroscopy | 3 | 2022 | 3 | 0.440 |
Why?
|
| Hispanic Americans | 4 | 2020 | 378 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 124 | 0.430 |
Why?
|
| Models, Statistical | 3 | 2019 | 173 | 0.420 |
Why?
|
| Pilot Projects | 3 | 2022 | 211 | 0.410 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2013 | 1 | 0.410 |
Why?
|
| African Americans | 4 | 2020 | 443 | 0.410 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 205 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 3 | 0.400 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 4 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 4 | 0.400 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 341 | 0.400 |
Why?
|
| Logistic Models | 7 | 2024 | 884 | 0.400 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2013 | 42 | 0.400 |
Why?
|
| Hospitals | 2 | 2011 | 76 | 0.400 |
Why?
|
| Machine Learning | 2 | 2023 | 53 | 0.390 |
Why?
|
| Treatment Outcome | 7 | 2019 | 1170 | 0.390 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2024 | 2 | 0.390 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 145 | 0.370 |
Why?
|
| Isotonic Solutions | 1 | 2011 | 1 | 0.360 |
Why?
|
| Sodium Chloride | 1 | 2011 | 3 | 0.360 |
Why?
|
| Debridement | 1 | 2010 | 3 | 0.340 |
Why?
|
| Pancreatectomy | 1 | 2010 | 2 | 0.340 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 5 | 0.340 |
Why?
|
| Young Adult | 7 | 2019 | 2473 | 0.330 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 677 | 0.330 |
Why?
|
| Pancreatic Diseases | 1 | 2009 | 1 | 0.330 |
Why?
|
| Registries | 3 | 2020 | 460 | 0.320 |
Why?
|
| Waiting Lists | 1 | 2009 | 12 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 27 | 0.310 |
Why?
|
| Abdominal Pain | 4 | 2021 | 14 | 0.310 |
Why?
|
| Asian Americans | 3 | 2020 | 164 | 0.300 |
Why?
|
| Cross Infection | 1 | 2008 | 25 | 0.290 |
Why?
|
| Pancreatic Juice | 4 | 2011 | 4 | 0.290 |
Why?
|
| Patient Discharge | 3 | 2019 | 154 | 0.280 |
Why?
|
| Adolescent | 5 | 2020 | 3533 | 0.280 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 381 | 0.270 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1287 | 0.270 |
Why?
|
| Cyanoacrylates | 1 | 2006 | 1 | 0.260 |
Why?
|
| Tissue Adhesives | 1 | 2006 | 1 | 0.260 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2006 | 4 | 0.260 |
Why?
|
| Age Factors | 5 | 2021 | 884 | 0.260 |
Why?
|
| Proteins | 3 | 2011 | 15 | 0.260 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 21 | 0.260 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 114 | 0.250 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 367 | 0.250 |
Why?
|
| Algorithms | 4 | 2013 | 226 | 0.250 |
Why?
|
| Radiography, Abdominal | 3 | 2012 | 3 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 300 | 0.240 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2019 | 4 | 0.230 |
Why?
|
| Blood Glucose | 2 | 2024 | 315 | 0.230 |
Why?
|
| Hypophosphatemia | 1 | 2024 | 2 | 0.220 |
Why?
|
| Diabetes Complications | 2 | 2020 | 106 | 0.200 |
Why?
|
| Smoking | 3 | 2021 | 428 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 120 | 0.200 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 12 | 0.200 |
Why?
|
| Double-Blind Method | 2 | 2022 | 142 | 0.200 |
Why?
|
| Pain Management | 2 | 2019 | 53 | 0.190 |
Why?
|
| Recurrence | 2 | 2022 | 165 | 0.190 |
Why?
|
| Secondary Prevention | 1 | 2022 | 48 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 55 | 0.190 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 42 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 24 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 198 | 0.180 |
Why?
|
| Food Intolerance | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proctitis | 1 | 2021 | 1 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 140 | 0.180 |
Why?
|
| Delphi Technique | 2 | 2019 | 29 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 11 | 0.170 |
Why?
|
| Stents | 2 | 2017 | 7 | 0.170 |
Why?
|
| Carcinoma | 1 | 2020 | 22 | 0.170 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 2 | 0.170 |
Why?
|
| Data Warehousing | 1 | 2020 | 3 | 0.170 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 10 | 0.170 |
Why?
|
| Glycemic Index | 1 | 2020 | 19 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 86 | 0.160 |
Why?
|
| Lysosomes | 1 | 2019 | 1 | 0.160 |
Why?
|
| Phagosomes | 1 | 2019 | 1 | 0.160 |
Why?
|
| Autophagy | 1 | 2019 | 3 | 0.160 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 13 | 0.160 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2019 | 6 | 0.160 |
Why?
|
| Warfarin | 1 | 2020 | 73 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 251 | 0.160 |
Why?
|
| Body Mass Index | 2 | 2020 | 937 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2019 | 24 | 0.150 |
Why?
|
| Patient Selection | 1 | 2020 | 178 | 0.150 |
Why?
|
| Los Angeles | 1 | 2019 | 139 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1155 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2018 | 75 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 175 | 0.140 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2018 | 87 | 0.140 |
Why?
|
| Sex Factors | 3 | 2021 | 607 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 173 | 0.140 |
Why?
|
| Syndrome | 1 | 2017 | 28 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2017 | 14 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 82 | 0.140 |
Why?
|
| Health Status | 1 | 2019 | 295 | 0.140 |
Why?
|
| Pravastatin | 1 | 2016 | 2 | 0.130 |
Why?
|
| Rosuvastatin Calcium | 1 | 2016 | 4 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Proteomics | 3 | 2011 | 9 | 0.130 |
Why?
|
| Vomiting | 2 | 2021 | 16 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2017 | 644 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2010 | 4 | 0.130 |
Why?
|
| Helicobacter pylori | 1 | 2016 | 24 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 53 | 0.130 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2015 | 1 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 148 | 0.120 |
Why?
|
| Netherlands | 2 | 2015 | 7 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 56 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 77 | 0.120 |
Why?
|
| Necrosis | 2 | 2016 | 3 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 311 | 0.120 |
Why?
|
| Mass Screening | 1 | 2020 | 671 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 58 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 707 | 0.110 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 2 | 0.110 |
Why?
|
| Mass Spectrometry | 2 | 2011 | 5 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 144 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 311 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 366 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2015 | 33 | 0.110 |
Why?
|
| Sigmoidoscopy | 1 | 2014 | 65 | 0.110 |
Why?
|
| Body Fluids | 2 | 2010 | 2 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1100 | 0.110 |
Why?
|
| Chromatography, Liquid | 2 | 2010 | 6 | 0.110 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2013 | 3 | 0.110 |
Why?
|
| Massachusetts | 2 | 2010 | 67 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2013 | 33 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 19 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 20 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 32 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mucin 5AC | 1 | 2012 | 1 | 0.100 |
Why?
|
| Intensive Care Units | 3 | 2024 | 101 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Telomerase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Mucin-2 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 21 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2012 | 23 | 0.100 |
Why?
|
| ras Proteins | 1 | 2012 | 20 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 20 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 1287 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Disease Progression | 3 | 2021 | 259 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 41 | 0.090 |
Why?
|
| Animals | 2 | 2024 | 280 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2019 | 306 | 0.090 |
Why?
|
| Plasma Substitutes | 1 | 2011 | 1 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 95 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 4 | 0.090 |
Why?
|
| New England | 1 | 2011 | 12 | 0.090 |
Why?
|
| Comorbidity | 2 | 2011 | 564 | 0.090 |
Why?
|
| Cytokines | 1 | 2011 | 30 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 58 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2011 | 60 | 0.090 |
Why?
|
| Duodenum | 1 | 2010 | 1 | 0.090 |
Why?
|
| Trypsin | 1 | 2010 | 1 | 0.090 |
Why?
|
| Proteome | 1 | 2010 | 2 | 0.090 |
Why?
|
| Nausea | 1 | 2010 | 8 | 0.090 |
Why?
|
| Diarrhea | 1 | 2010 | 12 | 0.090 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 3 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 6 | 0.090 |
Why?
|
| Prevalence | 3 | 2020 | 839 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2010 | 24 | 0.080 |
Why?
|
| Global Health | 1 | 2010 | 29 | 0.080 |
Why?
|
| Pain | 1 | 2010 | 75 | 0.080 |
Why?
|
| Morbidity | 1 | 2010 | 59 | 0.080 |
Why?
|
| Tomography | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2009 | 2 | 0.080 |
Why?
|
| Regional Health Planning | 1 | 2009 | 6 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2010 | 77 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 94 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2009 | 36 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 8 | 0.080 |
Why?
|
| Gallstones | 2 | 2019 | 14 | 0.080 |
Why?
|
| Risk | 1 | 2010 | 498 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2009 | 68 | 0.080 |
Why?
|
| Health Services Research | 1 | 2009 | 212 | 0.070 |
Why?
|
| Hospital Charges | 1 | 2008 | 8 | 0.070 |
Why?
|
| Inpatients | 1 | 2009 | 79 | 0.070 |
Why?
|
| Pennsylvania | 1 | 2008 | 26 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 218 | 0.070 |
Why?
|
| Diet | 1 | 2010 | 356 | 0.070 |
Why?
|
| SEER Program | 2 | 2020 | 94 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 355 | 0.070 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 1 | 0.070 |
Why?
|
| Medicare | 2 | 2020 | 201 | 0.070 |
Why?
|
| Phosphates | 1 | 2024 | 5 | 0.060 |
Why?
|
| APACHE | 2 | 2015 | 11 | 0.050 |
Why?
|
| Secretin | 2 | 2014 | 2 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 203 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2022 | 7 | 0.050 |
Why?
|
| Abdomen | 1 | 2022 | 20 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 73 | 0.050 |
Why?
|
| Rectum | 1 | 2021 | 14 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 280 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 83 | 0.040 |
Why?
|
| Ceruletide | 1 | 2019 | 1 | 0.040 |
Why?
|
| Membrane Fusion | 1 | 2019 | 2 | 0.040 |
Why?
|
| Nutritional Support | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Drainage | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hospitalists | 1 | 2019 | 8 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 96 | 0.040 |
Why?
|
| Gastroenterologists | 1 | 2019 | 7 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 40 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 64 | 0.040 |
Why?
|
| Surgeons | 1 | 2019 | 13 | 0.040 |
Why?
|
| Critical Care | 1 | 2020 | 67 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 127 | 0.040 |
Why?
|
| Poverty | 1 | 2020 | 165 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 160 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2011 | 405 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 112 | 0.040 |
Why?
|
| Medical Audit | 1 | 2017 | 36 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 24 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 814 | 0.030 |
Why?
|
| Pancreaticojejunostomy | 1 | 2016 | 1 | 0.030 |
Why?
|
| Narcotics | 1 | 2016 | 6 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2015 | 2 | 0.030 |
Why?
|
| American Medical Association | 1 | 2015 | 4 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 14 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 71 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pancreatic Elastase | 1 | 2014 | 1 | 0.030 |
Why?
|
| Steatorrhea | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Alcoholism | 1 | 2018 | 337 | 0.030 |
Why?
|
| Feces | 1 | 2014 | 85 | 0.030 |
Why?
|
| Spain | 1 | 2013 | 5 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 6 | 0.030 |
Why?
|
| Boston | 1 | 2013 | 28 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 171 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 2 | 0.030 |
Why?
|
| Genes, ras | 1 | 2013 | 5 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 21 | 0.030 |
Why?
|
| Mutation | 1 | 2013 | 132 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 12 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 17 | 0.020 |
Why?
|
| Digestive System Diseases | 1 | 2010 | 3 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 7 | 0.020 |
Why?
|
| Acetone | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 1 | 0.020 |
Why?
|
| Ethanol | 1 | 2010 | 21 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 145 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 210 | 0.020 |
Why?
|
| Bicarbonates | 1 | 2010 | 3 | 0.020 |
Why?
|